BROOKLYN
A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Underlying HeFH and/or ASCVD and LDL-C >100 mg/dL Who are Not Adequately Controlled by Their Lipid-Modifying Therapies
- Stage
- klaar
- Medicine
- Obicetrapib
- Population
- ASCVD
- Phase
- III
- First Patient In
- 18 November 2022
- Last Patient In
- 30 March 2023
- Last Patient Last Visit
- 20 May 2024
National Lead
dr. mr. A.J.M. Oude Ophuis
Cardioloog
Study Director
drs. H.G.R. Dorman
Cardioloog
Office Contact
